Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Afatinib in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Lung

Trial Profile

A Phase II Study of Afatinib in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Lung

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2018

At a glance

  • Drugs Afatinib (Primary) ; Pembrolizumab (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms Keynote 497; LUX-Lung IO
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 26 Nov 2018 Planned End Date changed from 25 Feb 2021 to 9 Oct 2020.
    • 31 Aug 2018 Biomarkers information updated
    • 21 Aug 2018 Planned primary completion date changed from 28 Jun 2019 to 29 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top